Company news

AtaiBeckley Inc. news in 2021

AtaiBeckley Inc.'s news releases, calls and decks from 2021, newest first.

View company

atai Impact Establishes the atai Fellowship Fund in Psychedelic Neuroscience with Massachusetts General Hospital’s Center for the Neuroscience of Psychedelics

December 15, 2021

Apeiron and Other Key Shareholders of atai Life Sciences Reinforce Support by Entering into Extended, Voluntary Share Lock-up Agreements

December 14, 2021

atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial of RL-007 in Cognitive Impairment Associated with Schizophrenia

December 13, 2021

atai Life Sciences Has Been Selected for Addition to the NASDAQ Biotechnology Index

December 12, 2021

atai Life Sciences launches TryptageniX to further expand atai’s robust intellectual property portfolio and strengthen atai's supply chain

December 8, 2021

atai Life Sciences Increases its Ownership Position in COMPASS Pathways

November 28, 2021

atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update

November 14, 2021

atai Life Sciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Business Update

November 7, 2021

atai Life Sciences to Participate in Upcoming November Investor Conferences

November 4, 2021

atai Life Sciences Announces Supportive Interim Data from First 8-Patient Cohort of Phase 2a Trial for Novel Treatment of Cognitive Impairment Associated with Schizophrenia

October 31, 2021

atai Life Sciences Launches atai Impact, a Philanthropic Program to Harness the Power of Innovative Mental Health Approaches for Positive Social Change

October 18, 2021

atai Life Sciences announces the launch of PsyProtix, to develop a precision psychiatry approach for Treatment-Resistant Depression (TRD)

October 10, 2021

atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx’s Graduation to Toronto Stock Exchange After Positive Early Feasibility Study Data

September 14, 2021

Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression

September 13, 2021

atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression

September 8, 2021

atai Life Sciences Reports Second Quarter 2021 Financial Results and Business Update

August 15, 2021

atai Launches Revixia Life Sciences to Develop Salvinorin A for a Variety of Mental Health Conditions

August 11, 2021

atai Life Sciences to Host Conference Call and Webcast to Discuss Second Quarter 2021 Financial Results and Provide Business Update

August 8, 2021

atai Life Sciences to Present at the 41st Annual Canaccord Genuity Growth Conference

August 5, 2021

atai Life Sciences launches InnarisBio, in partnership with the University of Queensland, with the aim to develop a more effective nose-to-brain delivery method for atai’s platform of mental health therapeutic programs

July 27, 2021

atai Life Sciences to Present at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit

July 6, 2021

atai Life Sciences Announces Pricing of Upsized Initial Public Offering

June 16, 2021

Calls in 2021

Decks in 2021